Summary
Becton Dickinson and Company (BDX) reported second-quarter fiscal year 2022 revenues of $4.641 billion, a slight increase of 0.7% year-over-year, driven by strong core product demand across its Medical and Interventional segments. The Life Sciences segment saw a notable revenue decline, primarily due to the lapping of significant COVID-19 testing sales from the prior year. Despite inflationary pressures on raw materials and freight, the company demonstrated resilience by improving gross profit margins through price management and cost efficiencies. The company completed the spin-off of its Diabetes Care business (Embecta Corp.) on April 1, 2022, with historical results now reflected as discontinued operations. This strategic move is expected to allow BDX to focus on its core medical technology segments. While the company faces ongoing macroeconomic challenges including inflation and supply chain disruptions, it continues to invest in growth initiatives and return value to shareholders through dividends. Management remains focused on its 'grow, simplify and empower' strategy to navigate the current environment.
Financial Highlights
54 data points| Revenue | $4.64B |
| Cost of Revenue | $2.57B |
| Gross Profit | $2.07B |
| R&D Expenses | $315.00M |
| SG&A Expenses | $1.15B |
| Operating Expenses | $4.10B |
| Operating Income | $537.00M |
| Interest Expense | $99.00M |
| Net Income | $360.00M |
| EPS (Basic) | $1.18 |
| EPS (Diluted) | $1.18 |
| Shares Outstanding (Basic) | 285.44M |
| Shares Outstanding (Diluted) | 287.30M |
Key Highlights
- 1Revenue for the three months ended June 30, 2022, was $4.641 billion, a modest increase of 0.7% compared to $4.607 billion in the prior year.
- 2Net income applicable to common shareholders decreased to $338 million from $502 million in the prior year, impacted by discontinued operations and other factors.
- 3Diluted Earnings per Share from Continuing Operations were $1.28 for the quarter, down from $1.32 in the prior year.
- 4The company successfully completed the spin-off of its Diabetes Care business (Embecta Corp.) on April 1, 2022, reflecting its strategic focus on core segments.
- 5Gross profit margin improved to 44.5% from 42.5% in the prior year's quarter, indicating effective cost management and pricing strategies.
- 6The company generated $1.498 billion in cash from continuing operating activities for the nine months ended June 30, 2022, demonstrating strong operational cash flow generation.